Table 1.

Anti-proliferative activities of the six GNF-7 analogs against melanoma cell lines harboring BRAF wt or class I/II/III mutants.

Entry	GI50 (μM) a
	-	Class I	Class I	Class II	Class III	Class III
	BRAF wt	BRAF V600E	BRAF V600E	BRAF G464E	BRAF G469E	BRAF D594G
	SK-MEL-2	SK-MEL-28	A375	C8161	WM3670	WM3629
vemurafenib	3.84 ± 0.04	0.49 ± 0.01	0.18 ± 0.02	5.81 ± 0.24	13.65 ± 0.89	33.10 ± 3.61
PLX8394	19.30 ± 2.02 **	0.53 ± 0.01	0.10 ± 0.04	27.30 ± 1.34 **	17.86 ± 0.31	27.95 ± 2.52
GNF-7	0.23 ± 0.08 ***	0.15 ± 0.02 *	0.06 ± 0.00	0.02 ± 0.00 ****	0.13 ± 0.01 ****	0.21 ± 0.00 ***
SIJ1227	0.05 ± 0.01 **	0.05 ± 0.01 **	0.04 ± 0.01	0.05 ± 0.01 ****	0.04 ± 0.00 ***	0.08 ± 0.00 **
SIJ1281	0.12 ± 0.01 ***	0.03 ± 0.01 ***	0.02 ± 0.00 *	0.02 ± 0.01 ****	0.03 ± 0.01 ***	0.03 ± 0.00 ***
SIJ1278	0.24 ± 0.03 ***	0.14 ± 0.02 *	0.09 ± 0.02	0.08 ± 0.01 ***	0.15 ± 0.00 ****	0.12 ± 0.00 ***
SIJ1777	0.02 ± 0.00 ***	0.04 ± 0.01 **	0.03 ± 0.00 *	0.03 ± 0.01 ****	0.04 ± 0.00 ****	0.04 ± 0.00 ***
SIJ1744	0.12 ± 0.01 ***	0.08 ± 0.01 **	0.02 ± 0.01 *	0.13 ± 0.06 **	0.13 ± 0.00 ****	0.08 ± 0.02 ***
SIJ1748	0.06 ± 0.00 **	0.02 ± 0.00 **	0.02 ± 0.01 *	0.03 ± 0.01 ***	0.12 ± 0.01 **	0.11 ± 0.02 ***
SIJ1787	0.03 ± 0.00 **	0.15 ± 0.00 *	0.03 ± 0.01 *	0.04 ± 0.02 ****	0.13 ± 0.01 ****	0.07 ± 0.01 ***

^a GI₅₀ represents the concentration which inhibits 50% of half-maximal growth. Each cell lines were treated with indicated compounds for 72 h. Averages with standard deviation (n = 3, duplicate) are presented. Statistical significances were determined using a one-way ANOVA analysis (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).